Feature|Articles|January 5, 2026

Top 5 conference coverage articles in 2025

Listen

0:00 / 0:00

Key Takeaways

The 340B program is under scrutiny for driving up costs, prompting calls for reform at the AMCP annual meeting.
Replacing Jardiance with Brenzavvy as a preferred SGLT2 inhibitor can lead to significant cost savings, according to industry experts.
Payers and providers are aligning on the 340B program, highlighting its complex dynamics and impact on drug pricing.
A novel metric, average daily heart per step (DHRPS), combines step counts with heart rate for enhanced health monitoring.
Actor Gary Sinise shared his personal experience with his son's sarcoma diagnosis, offering insights into the emotional impact of rare diseases.

Write-ups of presentations on the 340B Drug Pricing Program were among the most viewed conference-related articles on the MHE website in 2025.

340B Program Is driving up costs and needs urgent reform | AMCP Annual 2025

At the 2025 AMCP annual meeting in Houston, John M. O'Brien, Pharm.D., M.P.H., president and CEO of the National Pharmaceutical Council, shared concerns and potential reforms in a conversation with Managed Healthcare Executive

Removing Jardiance from the formulary | PBMI 2025

Jennie Barlow, Pharm.D., MBA, associate vice president, pharmacy industry relations for Scripius, discusses cost savings from removing Jardiance (empagliflozin) as a preferred SGLT2 inhibitor and replacing it with Brenzavvy (bexagliflozin).

340B makes for strange bedfellows | Asembia’s AXS25 Summit

Payers and some providers, often depicted as rivals, are on the same side when it comes to the 340B program that allows some hospitals to buy drugs at steep discounts, according to Milliman experts.

A step beyond: New metric combines step counts with heart rate | ACC 2025

The average daily heart per step (DHRPS) is computed by dividing the average daily heart rate, explains Zhanlin Chen, a Northwestern University Feinberg School of Medicine student.

Gary Sinise opens up about his son's death | Asembia's AXS25 Summit

The award-winning actor, perhaps best known for his supporting role in "Forrest Gump" expressed some regret as well as gratitude in talking about the death of his 33-year-old son from a rare form of sarcoma.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Top 5 conference coverage articles in 2025

Key Takeaways

340B Program Is driving up costs and needs urgent reform | AMCP Annual 2025

Removing Jardiance from the formulary | PBMI 2025

340B makes for strange bedfellows | Asembia’s AXS25 Summit

A step beyond: New metric combines step counts with heart rate | ACC 2025

Gary Sinise opens up about his son's death | Asembia's AXS25 Summit

Newsletter

Related Content

Telehealth is now a long-term part of Medicare mental health care

Predictions for 2026 on accountability, transparency and equity in U.S. healthcare by Elizabeth Mitchell, Keith Somers and more

Predictions for GLP-1s in 2026 from Luke Greenwalt, MBA, Whitney Stidom and Oren Mechanic, M.D., M.P.H.

Health Resources and Services Administration approves covered HPV self-test

GLP-1s outdo aspirin in colorectal cancer prevention, study finds | ASCO Gastrointestinal Cancers Symposium

Latest CME

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Arkansas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kentucky

“D” Is for Diagnosis: Decoding a Difficult Thoracic Malignancy – Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | New York

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Iowa

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Minnesota

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Wisconsin

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Arizona

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Nevada

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Indiana

2nd Annual Hawaii Cancer Conference

23rd Annual Winter Lung Cancer Conference®

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Arkansas

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Tennessee

Show Me the Data™: Incorporating the Latest Advances in Immunotherapy and EGFR-Targeted Treatments for Resectable Early-Stage NSCLC

Burst CME™: The Role of HER2 in NSCLC and Implications for Emerging Treatment Strategies

Future Directions in Treating SCLC and LCNEC-L: The Impact of DLL3

Community Practice Connections™: 19th Annual New York Lung Cancers Symposium®

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Huntington Beach Symposia

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

3rd Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

22nd Annual Winter Lung Cancer Conference®

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

27th Annual International Lung Cancer Congress®

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

26th Annual International Lung Cancer Congress

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

21st Annual New York Lung Cancers Symposium®

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

9th Annual School of Nursing Oncology™

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

20th Annual New York Lung Cancers Symposium®

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

(Pharmacist Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Trending on Managed Healthcare Executive

CDC slashes list of recommended childhood vaccinations from 17 to 11

Prescribing prevention: How nutrition access is reshaping affordable healthcare

What to know about ATTR-CM and treatment options

GLP-1s outdo aspirin in colorectal cancer prevention, study finds | ASCO Gastrointestinal Cancers Symposium

Medicaid expansion linked to rising PrEP use, improved HIV prevention